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Background. Mitochondrial encephalomyopathies are a heterogeneous group of clinical disorders generally caused due to
mutations in either mitochondrial DNA (mtDNA) or nuclear genes encoding oxidative phosphorylation (OXPHOS). We analyzed
the mtDNA sequences from a group of 23 pediatric patients with clinical and morphological features of mitochondrial
encephalopathies and tried to establish a relationship of identified variants with the disease. Methodology/Principle
Findings. Complete mitochondrial genomes were amplified by PCR and sequenced by automated DNA sequencing.
Sequencing data was analyzed by SeqScape software and also confirmed by BLASTn program. Nucleotide sequences were
compared with the revised Cambridge reference sequence (CRS) and sequences present in mitochondrial databases. The data
obtained shows that a number of known and novel mtDNA variants were associated with the disease. Most of the non-
synonymous variants were heteroplasmic (A4136G, A9194G and T11916A) suggesting their possibility of being pathogenic in
nature. Some of the missense variants although homoplasmic were showing changes in highly conserved amino acids (T3394C,
T3866C, and G9804A) and were previously identified with diseased conditions. Similarly, two other variants found in tRNA
genes (G5783A and C8309T) could alter the secondary structure of Cys-tRNA and Lys-tRNA. Most of the variants occurred in
single cases; however, a few occurred in more than one case (e.g. G5783A and A10149T). Conclusions and Significance. The
mtDNA variants identified in this study could be the possible cause of mitochondrial encephalomyopathies with childhood
onset in the patient group. Our study further strengthens the pathogenic score of known variants previously reported as
provisionally pathogenic in mitochondrial diseases. The novel variants found in the present study can be potential candidates
for further investigations to establish the relationship between their incidence and role in expressing the disease phenotype.
This study will be useful in genetic diagnosis and counseling of mitochondrial diseases in India as well as worldwide.
Citation: Wani AA, Ahanger SH, Bapat SA, Rangrez AY, Hingankar N, et al (2007) Analysis of Mitochondrial DNA Sequences in Childhood
Encephalomyopathies Reveals New Disease-Associated Variants. PLoS ONE 2(9): e942. doi:10.1371/journal.pone.0000942
INTRODUCTION
Mitochondria are keys to many a cellular processes. One of the most
important mechanisms is oxidative phosphorylation (OXPHOS)
resulting in the production of cellular energy in the form of ATP.
The OXPHOS system consists of five multiprotein complexes (I–V)
and two mobile electron carriers (coenzyme Q and cytochrome c)
embedded in the lipid bilayer of the inner mitochondrial membrane
[1,2]. The mitochondrial genome encodes 13 essential polypeptides
of the OXPHOS system and the necessary RNAs machinery (two
ribosomal RNAs and 22 transfer RNAs). The remaining structural
proteins and those involved in import, assembly and mitochondrial
DNA (mtDNA)replicationare encoded bythe nuclearDNAand are
targeted to the mitochondria.
Disorders of mitochondrial origin are a heterogeneous group of
diseases commonly manifesting in tissues with high-energy demand,
for example, muscle, nerve, and eye. Mutations in respiratory chain
protein subunits encoded by either mitochondrial DNA (mtDNA) or
nuclear DNA are responsible for such diseases [3]. Mutations in
mtDNAaremorecommonthaninnuclearDNAbecausetheformer
mutates 10–17 times faster than later. The reason for high mutation
rate is the absence of chromatin and histones. Also the continuous
generation of reactive oxygen species (ROS) and the lack of efficient
repairing mechanism further increases the mutation rate [4].
Diagnosis of mitochondrial disorders depends on a combination
of approaches including clinical analysis, measurement of re-
spiratory chain enzyme activities and morphological analysis.
Genetic diagnosis involves the analyses of mutations; mostly those
known as primary mutations (disease associated) of mtDNA.
Pathogenic mtDNA point mutations are present either in tRNA or
in protein coding regions. A number of human genetic diseases of
mitochondrial origin have been elucidated [5,6]. An mtDNA
mutation can inherit maternally or arise sporadically. Most of the
pathogenic mtDNA mutations are heteroplasmic (a mixture of
both mutant and wild type mtDNA in the same cell or tissue) and
the disease manifestations or clinical expression depends on the
ratio of mutant to wild type mtDNA [7]. However, in case of
Leber’s hereditary optic neuropathy (LHON) and non-syndromic
sensoneural hearing loss, the mutations are almost homoplasmic
and only a few cases of heteroplasmy have been observed [8–10].
Recent studies have shown that majority of mutations associated
with mitochondrial diseases remain unidentified occurring either
in mtDNA or nuclear DNA [11]. Mostly the diagnosis is based on
Academic Editor: Philip Awadalla, North Carolina State University, United States
of America
Received June 10, 2007; Accepted August 30, 2007; Published September 26,
2007
Copyright:  2007 Wani et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This study was supported by a grant from Department of Bio-
technology, India. Wani A.A. is Senior Research fellow of Council of Scientific and
Industrial Research (CSIR), India.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: yogesh@nccs.res.in
PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e942primary mutations for diseases like LHON, Leigh’s disease,
NARP, MELAS etc. However, in majority of the cases, no
primary mutations are being detected even if the patient has
typical signs of mitochondrial disorder. Recent studies have shown
the role of secondary mutations and involvement of other rare or
novel mtDNA variants in mitochondrial encephalomyopathies
[12–17]. The existence of unique and new variants specific to
particular populations makes the diagnosis more complicated.
Several researchers are analyzing the complete mtDNA
sequences in mitochondrial disorders and have reported a variety
of new variants whose mechanism of involvement in the disease is
not well established. [13–15]. These variants may be found either
in protein coding region, in tRNA or very rarely in rRNA genes
and are considered to be rare or secondary. A few of these variants
have been found in more than one case. Hence, further evidence
of these secondary, rare or novel variants is acceptable and it
becomes necessary to explore more mtDNA sequences in patients
with mitochondrial disorders to establish the relationship of each
variant with the disease.
In the present study, we explored the mtDNA sequences of 23
patients (children) with clinical and morphological features of
typical mitochondrial dysfunction and efforts were made to
establish the relationship of each variant with the disease. Also,
this study is aimed to establish a genetic diagnosis mechanism for
mitochondriopathies particularly relevant to Indian subcontinent
and may also be applicable to other populations.
MATERIALS AND METHODS
Patients and families
A group of 23 pediatric patients clinically diagnosed for
mitochondrial disorders were studied. Out of these, 6 were
diagnosed with Leigh’s syndrome or Leigh’s like syndrome, one with
MELAS and one with chronic progressive external opthalmoplegia
(CPEO). The remaining 15 patients had undefined mitochondrial
myopathies or encephalopathies. All the patients had the classical
clinical features such as stroke like episodes, neuropathy, seizures,
ataxia, optic atrophies, etc. The primary clinical diagnosis was based
on high blood and serum lactate levels following the rules of Berner
et al. 2002 [18]. No histopathology was done because of not getting
the skeletal muscle biopsies due to some ethical issues. The Magnetic
Resonance Imaging (MRI) findings were also taken into consider-
ation. Detailed laboratory findings are shown in table 1. Respiratory
chain enzyme analysis was done for 14 patients using either primary
lymphocytes or established lymphoblast cell lines (Table 2). Majority
of the subjects were below the age of 10 years except patient 8 and
patient 9 whose ages were 12 and 19 years respectively.
The present study was conducted in accordance with the
Helsinki Declaration of 1975, as revised in 2000. Blood samples
were collected by the expert physicians of three major hospitals in
India (namely KEM hospital, Mumbai, Wadia Hospital for
children, Mumbai and P.D. Hinduja hospital, Mumbai). A written
consent was obtained from parents of all patients included in the
study. It is to be noticed that there were no familial relations
among the 23 pediatric patients studied.
Cells
In majority of the patients, primary lymphocytes isolated by Ficoll-
Hypaque gradients were used for respiratory chain enzyme (RCE)
analysis. However, in 6 patients due to less sample volume available,
RCE was performed with lymphoblast cell lines established using
Epstein bar virus (EBV) transformation. The cells were maintained
in RPMI 1640 medium (Gibco BRL) supplemented with 10% (v/v)
heat inactivated fetal bovine serum (Gibco BRL).
Respiratory Chain enzyme analysis and Rotenone
sensitivity
Activities of respiratory chain enzymes viz., NADH dehydroge-
nase (Complex I), Succinate dehydrogenase (Complex II),
Succinate cytochrome C reductase (Complex II+III), and
ubiquinol Ferricytochrome C oxidoreductase (Complex III) were
determined spectrophotometrically using methods of Trounce et.
al [19]. The cytochrome C oxidase (Complex IV) activity was
determined by using cytochrome C oxidase kit (Sigma, USA) as
per manufacture’s instructions. Mitochondrial complex I activity
was taken as the rate sensitive to rotenone inhibition (10 mM).
Results were expressed as citrate synthase ratios to correct for any
differences in sample preparation. For each assay, results are
interpreted as the mean of three independent experiments.
Extraction and PCR amplification of DNA
Total genomic DNA was extracted from the blood using DNeasy
tissue kit (Qiagen, Germany). The entire mitochondrial genome was
amplified in 1–3 kb overlapping fragments using a subset of 24
primer pairs as described earlier [20]. The PCR reaction mixture
consisted of 16reaction buffer, 2 mM of primers, and 125 mMo f
dNTPs, 0.1 mg of template DNA and 1 unit of AmpliTaq gold DNA
polymerase (Applied Biosystems, USA). The standardized PCR
conditions were: initial denaturation at 95uCf o r2m i n u t e s ,3 5c y c l e s
Table 1. Laboratory findings of children with mitochondrial
disease.
......................................................................
Disorder Patients
Age
(years)
CSF lactate
(mg/dl)
Blood Lactate
(mg/dl)
Encephalopathy P1 7 28.8 ND
P3 0.3 22.0 ND
P4 7 ND 26.2
P10 4 ND 26.2
P11 6 14 16.7
P12 1 47.4 ND
P15 0.6 High ND
P17 9.5 18.7 20.2
P19 2.5 17.1 29.8
P20 3 20 ND
P23 1.8 High ND
Leigh’s disease P2 2.5 46.7 47.5
P5 0.7 18.25 ND
P6 4 36.1 ND
P14 1 Normal ND
P18 1 39.4 ND
P22 7 26.2 ND
Mitochondrial cytopathy P7 1.8 High ND
P13 7 26.2 31.0
P16 2 ND ND
P21 7 29 ND
CPEO P8 19 15 ND
MELAS P9 12 26 27
ND=not determined, CSF=cerebrospinal fluid; CPEO=chronic progressive
external opthalmoplagia, MELAS=Mitochondrial encephalopathy lactic acidosis
and stroke like episodes. Normal range for CSF and Blood lactate is 10.8-
18.9 mg/dl.
doi:10.1371/journal.pone.0000942.t001
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e942of denaturation at 94uC for 45 seconds, annealing at 60uCf o r
45 seconds,extensionat72uCfor90 secondsandafinalextensionat
72uC for 10 min. mtDNA was amplified by 22 overlapping PCR
fragments of 800 base pairs to .1 kb. To detect the amplified DNA,
10 ml of PCR product was electrophoresed on a 1% agarose gel and
visualized by ethidium bromide staining. The use of large PCR
products excluded the possibility that nuclear pseudogenes present
will complicate the analysis [21]. The presence of deletions was
excluded by long-range PCR (Expand Long PCR, Roche,
Germany) in the blood DNA.
DNA sequencing and Variant identification
Excess primers and dNTPs were removed from the PCR amplified
DNA fragments using 0.5 unit of shrimp alkaline phosphatase
(Amersham pharamacia, USA) and 2 units of Exonuclease I
(Amersham). The fragments were then cycle sequenced using
Bigdye terminator cycle sequencing kit with a thermostable
thermsequenase II DNA Polymerase. The products were pre-
cipitated using salt/ethanol to remove all unincorporated dye
labeled terminators, and the pellet was diluted in formamide
loading dye and analyzed with an ABI 3730 sequencing
Table 2. Activities of oxidative phosphorylation enzyme complexes in patient and control lymphoblast cell lines.
..................................................................................................................................................
Enzyme Complexes
Patient I II II+III III IV CS
Patient 1 9.7* 14 24.33 62.91 333.7 319.43
Patient 2 20.2865.55* 12.7862.84 22.8464.08 56.84 612.35 227.9635.48 289.8768.54
Patient 3 28.4 14.1 24.85 59.91 188.7* 293.09
Patient 4 24.5665.74* 12.9861.36 21.2462.55 70.57614.0 372.34644.88 325.50612.0
Patient 5 12.3* 12.77 23.0 63.10 362.1 328.77
Patient 6 13.8464.36* 12.7861.64 39.7266.8 62.78629.89 299.76 51** 292.62 633.84
Patient 7 12.84* 13.0 25.00 35.10* 228.4 322.01
Patient 9 8.5* 12.33 23.10 52.33 140.4** 330.41
Patient 10 12.8462.0** 13.3661.36 24.9264.08 64.19612.28 414.00653.13 317.31613.0
Patient 12 34.0 11.97 23.98 56.10 247.1 299.80
Patient 13 10.3* 13.75 24.87 39.13* 235.3 311.23
Patient 14 36.0 13.36 25.50 59.10 340.8 301.43
Patient 19 8.23* 12.47 26.00 65.10 351.2 318.09
Controls (n=3) 48.4065.23 12.8862.42 25.1664.30 64.4068.86 379.59646.81 276.15615.5
Mitochondrial complex I activity was taken as the one that is rotenone sensitive. Specific enzyme activities shown as nmol/min/mg protein. I; NADH-DB oxidoreductase,
II; Succinate-DB oxidoreductase, II+III; Succinate Cytochrome C reductase, IV; Cytochrome C oxidase, CS; Citrate synthase. ** and * indicate P values that are stastically
significant (p,0. 05 and p,0.005). SD6 was calculated for only five cell lines.
doi:10.1371/journal.pone.0000942.t002
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Figure 1. Ethidium Bromide stained polyacrylamide gels of PCR amplified products encompassing heteroplasmic variants G4812C, A4136G,
A9194G, A10149T and T11916A analyzed by PCR-RFLP in patients and their respective mothers. Mutation G4812C causes a loss of Dde I site and
hence shows a single band after digestion whereas wild type fragment shows 2 bands (bp). Variant A4136G creates an Nla III site and after digestion
results in two bands of 43 bp and 107 bp. The heteroplasmic mutation has three bands (43 bp, 107 bp and 150 bp) as shown. Similarly other variants
e.g. A9194G (creates Hha I site), A10149T (creates Dde I site) and T11916A (creates Rsa I site) and all result in 3 bands after digestion and separation on
12% PAGE. The homoplasmic mutations should yield only 2 bands lacking the wildtype band after separation on PAGE.
doi:10.1371/journal.pone.0000942.g001
Childhood Encephalomyopathies
PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e942instrument (Applied Biosystems, USA). Both forward and reverse
primers were used for sequencing.
Sequence data was analyzed for mutations by ABI software
(SeqScape version 2.1) and also confirmed by BLASTn program.
All the nucleotide sequences were compared with the revised
Cambridge reference sequence (CRS) [22] and with those present
in two mitochondrial databases; MITOMAP (http://www.mito-
map.org) and Human mitochondrial genome database (http://
www.genpat.uu.se/mtDB). When the genomic change was located
in an encoding region, we used the Mitoanalyzer programme
(http://www.cstl.nist) to determine whether the mutation trig-
gered any amino acid change in the polypeptide sequence. All the
identified variants were also tested in patient’s mothers to find out
whether they are maternally inherited or are of de novo origin.
Analysis of heteroplasmy
We considered heteroplasmic variants as those producing double
peaks in the electropherograms. All heteroplasmic variants present
in protein coding regions, were further confirmed by PCR/RFLP
(restriction fragment length polymorphism) analysis. RFLP was
performed for only those variants that do create a restriction site.
However, some variants did not create any restriction site; hence
heteroplasmy for such variants was considered on the basis of
double peaks in the sequence electropherograms. For RFLP,
amplified DNA was digested in a 50-ml-reaction volume with 5U
of restriction enzyme. The mixture was incubated at 37uC for
3 hr, electrophoresed on a 12% Polyacrylamide gel (PAGE) in 26
Tris acetate buffer (TAE) buffer and visualized with ethidium
bromide staining (Fig. 1). Enzyme digestion analysis was applied to
patients and their respective maternal relatives. Densitometry was
used to calculate the amount of wild type and mutated DNA.
Bioinformatics analysis
To understand the consequences of these mutations upon the
structure and interaction of protein subunits, we plotted the
hydropathy indices for a moving 9-residue window for both the
wild type and mutant polypeptides using Kyte-Doolittle hydrop-
athy plot analysis (http://www.gcat.davidson.edu/rankarin/kyte-
doolittle.htm) [23]. Kyte-Doolittle plot predicts the possible
structure of a protein. Further, the membrane-spanning regions
of these proteins were predicted from the SPLIT 4.0 server
(http://split.pmfst.hr/split/4/). The purpose of this server is to
predict the trasmembrane (TM) secondary structures of mem-
brane proteins using the method of preference functions.
Table 3. Novel and known mtDNA substitutions in patients with mitochondrial encephalomyopathies.
..................................................................................................................................................
Patient Mutation Gene affected Amino acid change Disease association MITOMAP/mtDB Status
P1 T4216C ND1 Tyrosine-Histidine LHON P. M
G4812C ND2 Valine-Leucine Novel Not known
P2 T11916A * ND4 Phenylalanine-Tyrosine Novel Not known
P3 T4216C ND1 Tyrosine-Histidine Known P. M
P4 T3866C ND1 Isoleucine-Threonine LHON P. M
P5 2074 del-A 16SrRNA Not applicable Novel Not known
A10149T ND3 Methionine-Valine Novel Not known
P6 C4640A ND2 Isoleucine-Methionine LHON Provisional
G15812A Cytochrome b Valine-methionine LHON Secondary
15943 del –T tRNA threonine Not applicable Novel Not known
P7 G5783A * tRNA cysteine Not applicable Myopathy; Deafness Provisional
P8 A10149T * ND3 Methionine-leucine Novel Not known
P9 A3243G * tRNA leucine Not applicable MELAS Confirmed pathogenic
P10 T3394C ND1 Tyrosine-Histidine LHON/NIDDM Unclear
P12 G3736A ND1 Valine-Isoleucine Novel Not known
C8309T* tRNA lysine Not applicable Novel Not Known
P13 G5783A * tRNA Cysteine Not applicable Myopathy; Deafness Provisional
P14 A9194G* ATPase 6 histidine-Aspargine Novel Not known
P16 T654G 12S rRNA Not applicable Novel Not known
T2248C 16S rRNA Not applicable Novel Not known
A15924G tRNA threonine Not applicable LIMM P. M
P17 G9804A COX III Alanine-threonine LHON Provisional
P18 A4704T ND2 Methionine-Leucine Novel Not known
P19 A4136G* ND1 Tyrosine-Cysteine LHON Provisional
P22 G5783A* tRNA cysteine Not applicable Myopathy; Deafness Provisional
G7269A COX I Valine-methionine Novel Not known
P23 T8424C ATPase 8 leucine-proline Novel Not known
Asterisks (*) indicate the variants that are heteroplasmic. ND1, ND2, ND3, ND4 and ND5 are subunits of NADH dehydrogenase (Complex-I). COX-I and COX-III are the
subunits of Cytochrome C oxidase (Complex-IV), AD/PD is Alzeimer’s Disease and Parkinsons’s Disease. Provisional status indicates that only one group has reported the
mutation as pathologic. P.M. (point mutation / polymorphism) status indicates that some published reports have determined the mutation to be a non-pathogenic
polymorphism. mtDB is Human Mitochondrial genome database (http://www.genpat.uu.se/mtDB).
doi:10.1371/journal.pone.0000942.t003
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e942Secondary structures of tRNAs were accessed by using the
RNA2 programme at the following website: http://www.genebee.
msu.su/services/rna2_reduced.html.
RESULTS
We sequenced the mitochondrial genomes of 23 patients with
probable encephalopathy and identified a total of 27 significant
variants or mutations. Out of these, 12 are novel mutations and
remaining 15 are already known mutations associated with
mitochondrial diseases (Table 3). Those variants, which do not
cause any amino acid change and already reported as polymorph-
isms in databases, were not considered to be significant and were
excluded from further analysis (data not shown). The site of these
mutations are as follows: 16 in the protein coding regions (out of
which 12 are present in subunits of mitochondrial complex-I genes),
3 in ribosomal RNA, 3 in tRNA coding genes, 2 in complex IV, 1 in
cytochrome b and 2 in complex-V genes (ATP synthase). Only one
primary disease associated tRNA mutation A3243G was observed in
a MELAS patient. Most of the mutations were specifically present in
only one case, except G5783A, T4216C and A10149T. Variant
G5783A was found in three patients (P7, P13, and P22), whereas
variant T4216C (P1 and P3) and variant T10149A (P5 and P8) were
found in two cases each. None of the novel variants were found in
any of the 105 control mtDNA sequences from Indian population
(http://www.mitomap.org and www.genpat.use/mtDB). A few of
the known variants viz., T3394C, T3866C, A4136G, T4216C,
C4640A,G5460A,G5783AandG9804A(Table3)werefound tobe
associated with the disease earlier (MITOMAP). Amongst these,
variants T3394C, T3866C, A4136G, T4216C and G9804A [in
COX III subunit] are considered to be secondary in Leber’s
hereditaryopticneuropathy(LHON)[12,24–26].Patientsharboring
variants A4136G, C4640A, and G9804A did not have LHON but
other clinical symptoms of mitochondrial disease were evident. The
visual acuity of these patients was not affected. Variant T3866C
caused extended imbalance in hydrophobicity of mutant ND1
peptidegeneratedwiththe Kyte-Doolittle algorithm (as evident from
its hydropathy plot). This substitution not only substantially reduced
the hydrophobicity of extramatrix coil but also influenced the
contiguous intra membrane helical domain (Fig. 2). The hydropathy
plot was not significantly altered by other variants (data not shown).
Variant T4216C occurred to a considerable extent in controls
and there are evidences of association of this with LHON (https://
www.mitomap.org), however its pathogenicity is not established
and there are many controversies. Other homoplasmic variants
(e.g. G3736A, A4704T, and G7269A) even though novel did not
fulfill all the pathogenicity criteria (not present in MITOMAP and
Human mitochondrial genome databases (www.genpat.uu.se/
mtDB)). Hence, these might not be significant in terms of
pathogenicity and were classified as polymorphisms.
In the present study, some of the variants occurred either singly
or in association with other known or novel variants in protein
coding or tRNA genes (Table 3). In certain cases, more than one
secondary pathogenic variant was found in a single patient (For
example, P6 harboring 3 provisionally pathogenic variants:
C4640A, G15812A and novel 15943del-T). This typical combi-
nation of mtDNA variants (two of them associated with
mitochondrial disorders earlier) found in P6 was not found in
any of the control mtDNA sequences. This explains that
Figure 2. Kyte-Doolittle Hydropathy Plot of wild type and mutated NADH Dehydrogenase Subunits (ND1). Mutation T3866C (Isoleucine-Valine)
showing a significant decrease in hydrophobicity at amino acid position 187 in the ND1 protein. SPLIT 4.0 plots predicting Tran membrane regions
and alterations in them due to mutation T3866C. Black line is indicative of wild type whereas red line indicates the mutated polypeptide.
doi:10.1371/journal.pone.0000942.g002
Childhood Encephalomyopathies
PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e942mitochondrial disease can occur due to more than one variant in
the mitochondrial genome and may produce a typical clinical
phenotype that complicates the diagnosis.
We also observed six heteroplasmic variants viz., G5783A in
three cases (P7, P13 and P22), C8309T in one case (P12), G4136A
in one case (P19) and T10149A in two cases (P5 and P8). The
novel variants T11916A (P2) and A9194G (P14) were found singly.
We performed PCR-RFLP analysis for most of the heteroplasmic
nucleotide changes (Fig. 1). Unfortunately, due to very less amount
of DNA available, we could not estimate the accurate percentage
of heteroplasmy by densitometry to repeat the digestion of DNA.
Out of these heteroplasmic variants, mutation G5783A in Cys-
tRNA and A4136G (TyrRCys) are already listed in the
MITOMAP. The former being reported from patients with
encephalomyopathy and cardiomyopathy [15] and the latter from
LHON cases [27]. However, in our study, the patient (P19)
harboring A4136G variant did not have LHON but had typical
symptoms of mitochondrial disease with brain involvement.
Another heteroplasmic variant T10149A was found associated
with two cases (Table 3, Fig. 1).
Two novel variants were observed in ATPase subunits, one
heteroplasmic A9194G in ATP6 (P14) and other homoplasmic
T8424C in ATP 8 subunit (P23). The novel tRNA mutation
C8309T found in one case (P12) alters the structure of tRNA
lysine to a higher extent (Fig. 3). The mutation A9194G changes
highly conserved histidine residue to arginine and mutation
T8424C changes a conserved leucine to proline (Fig. 4).
All the variants reported in present study were maternally
inherited because they were also detected in the mtDNA of their
respective mothers. The mothers were asymptomatic and do not
express the disease phenotype. However, in some cases (n=6), the
other family members or siblings were also showing the disease
symptoms. Moreover, the variants were not located in the
pseudogenes of the nuclear genome because the primers used for
PCR reaction did not amplify the nuclear product when the DNA
from rho zero cells (kindly provided by Dr. Taylor, New Castle,
UK) were used.
DISCUSSION
Complete mitochondrial genome sequencing of patients with
childhood encephalopathies allowed us to detect mtDNA variants
that can be associated with the disease. We located heteroplasmic
mutations in the tRNA genes of five children, one of which is novel
C8309T in Lys-tRNA and the other in Cys-tRNA (G5783A) in
three patients. One patient had the common MELAS mutation
(A3243G). In addition, we found several mutations (A4136G,
C4640A, T3394C, G9804A, A9194G) in protein coding region
that have been previously reported from LHON and related
disorders.
We believe that the mutations A4136G, A9194G and T11916A
are the cause of encephalopathy in the patients P18, P2 and P14
respectively. A complex-I deficiency was evident in patients
harboring A4136G and T11916A variants (Table 2). These three
mutations were absent in 105 healthy control sequences.
Alignment of ND1, ND3 and ATPase 6 sequences from various
species revealed highly conserved nature of tyrosine; phenylala-
nine and histidine at these positions in all mammals and other
eukaryotes (Fig. 4). Furthermore, these mutations were hetero-
plasmic in blood which is typical characteristic of pathogenic
mutations in mtDNA. The heteroplasmy levels were clear from the
RFLP patterns (Fig. 1). The higher percentage of mutant DNA in
Figure 3. Changes in the secondary structure of tRNA lysine caused by variant C8309T identified in Patient-13. The free energy of the cloverleaf
structure is significantly increased in the mutated tRNA lysine.
doi:10.1371/journal.pone.0000942.g003
Childhood Encephalomyopathies
PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e942the proband might explain the severity of clinical phenotypes.
However,thepathogenic relevanceof variant A10149T isdifficultto
establish because it is satisfying only a few criteria of pathogenicity
such as heteroplasmic nature in blood, a change in moderately-
conserved methionine to leucine in ND4 subunit of complex-I
(Fig. 4), and is absent in controls. On the other hand, it did not
segregate with the clinical phenotype because it occurred in two
patients with different clinical findings and its association with rRNA
deletion (in P3) or tRNA variant (in P9) might be modulating the
phenotype of these two patients. Therefore, A10149T can be
classified as a variation of unknown pathogenic relevance. However,
our present analysis showed that it does not belong to the common
polymorphisms associated with Indian populations [28,29].
The pathogenic relevance of some homoplasmic variants
(T3394C, T3866C, C4640A and G9804A) is also unclear. The
patients harboring these mutations did not have LHON but had
symptoms of typical childhood encephalopathies. The significance
of homoplasmic variations in mtDNA remains uncertain, though
several homoplasmic mutations have been implied in disease
processes. The high degree of polymorphic variability is a major
disadvantage in assessing the pathogenicity of a new base change.
In addition, polymorphisms might be relatively rare and might co-
segregate with disease, confounding identification of the patho-
genic mutation. There are exceptions to the rules of classical
pathogenic mtDNA mutations, which are defined as a category of
human, maternally inherited disorders characterized by a homo-
plasmic mtDNA pathogenic mutation with variable penetration
and stereotypic clinical expression. These disorders include
LHON, mitochondrial non-syndromic sensorineural hearing loss,
and a form of mitochondrial hypertrophic cardiomyopathy [8].
Recently, a non-synonymous homoplasmic mitochondrial DNA
mutation was reported to be associated with severe COX
deficiency, multiple neonatal deaths and Leigh’s syndrome [30].
Homoplasmic mitochondrial tRNA variants are considerably
under-estimated as a cause of mitochondrial disorders, and they
may indeed play a greater role in the development of
cardiomyopathy than previously reported [31]. Further analysis
of more patients will be helpful to prove the association of
Figure 4. Evolutionary conservation of novel and known amino acid changes in the studied patients. The mtDNA sequences for ND1, ND2, ND3,
ND4, COX 3, ATPase 6 and ATPase 8 protein subunits of different mammalian species were converted to protein sequence by Gene Runner software.
The amino acid sequences were aligned by Clustal6programme. Accession numbers for the mtDNA sequences used for alignment are: Human
(NC_001807), Gorilla (NC_001645), Chimpanzee (NC_001643), Orangutan (NC_001646), Bovine (NC_006853), Dog (NC_002008), Pig (NC_000845), Rat
(NC_001665), and Mouse (NC_005089).
doi:10.1371/journal.pone.0000942.g004
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isms with mitochondrial diseases. However, the complex I defect
in such patients can be possibly because of some unknown
mutations in nuclear genes encoding OXPHOS proteins and
assembly factors.
Interestingly, we found three tRNA mutations (A3243G,
G5783A and C8309T) in 5 out of 23 patients i.e. 21.7% of
studied patient group out of which G5783A was present in 3
patients (13.07% of patient group). Thus, it can be confirmed that
this mutation is a potential pathogenic mutation. Our results are in
agreement with earlier studies which showed mitochondrial tRNA
mutations in 18% of encephalomyopathic cases [32].
Given the clinical features and the absence of mtDNA deletions
in the above studied patients, the novel as well as known disease
associated mtDNA variants which we have identified may well
play a direct or indirect role in causing the disease. Two or more
variants in the same patient might also have a role in explaining
the diversity of clinical phenotypes. In addition, we found many
other known polymorphisms which were non-significant and non-
pathogenic so were excluded from our analysis. Some of these
variants define Indian population specific haplogroup (e.g.
A10398G, C10400T) found in 80% of the controls and other
mutations (A8860G, A8701G, A4769G, A1438G, A15326G,
C7028T, C12705T) were found in nearly 50% of the control
mtDNA sequences. However, a different genetic mitochondrial
background can further determine the phenotype or as previously
known that environmental factors could interact with genetic factors
(mitochondrial or nuclear or both) amplifying their effect [33,34].
In conclusion, complete mitochondrial genome sequencing
allowed us to detect both novel and already known variants in
children who presented with unexplained encephalopathy and
combination of neuromuscular/non-neuromuscular defects with
OXPHOS defects. The known mutations identified in this study
were already described in association with diseases in one or more
cases. Hence, our study further strengthens their involvement in
disease and potential pathogenicity which could be correlated in
future with diagnosis of the mitochondrial diseases. The novel
variants found in present study can be potential candidates for
further studies to establish the relationship between their incidence
and their role in determining disease. However, we were left with 7
children who did not have any pathogenic (confirmed, provisional
or disease-associated polymorphisms) mutations in mtDNA,
suggesting that the likelihood of nuclear gene mutations in
children with a mitochondrial encephalopathy may be even
higher than that of mtDNA mutations. Hence, the effect of nuclear
genetic factors or nuclear genes encoding mitochondrial proteins
cannot be ignored.
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